Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Alteration of CD1 expression in multiple sclerosis.
[Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal.]
Breastfeeding is associated with lower risk for multiple sclerosis.
Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk.
Graves' disease after treatment with Alemtuzumab for multiple sclerosis.
Can smoking aggravate my multiple sclerosis symptoms?
Obstructive sleep apnea and fatigue in patients with multiple sclerosis.
Brain Region-specific Alterations in the Gene Expression of Cytokines, Immune Cell Markers and Cholinergic System Components During Peripheral Endotoxin-induced Inflammation.
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
Social cognition in pediatric-onset multiple sclerosis (MS).
In situ expansion of T cells that recognize distinct self-antigens sustains autoimmunity in the CNS.
Alemtuzumab 3-year data show durable effect on MS disability
Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses.
In Active Relapsing-Remitting Multiple Sclerosis, Effector T Cell Resistance to Adaptive Tregs Involves IL-6-Mediated Signaling.
The genetics of multiple sclerosis.
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis.
Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
In vitro screening of NADPH oxidase inhibitors and in vivo effects of L-leucinethiol on experimental autoimmune encephalomyelitis-induced mice.
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels.
Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis.
Comorbid Multiple Sclerosis and TDP-43 Proteinopathy in a Gulf War Sea Captain.
Riluzole enhances glutamate uptake in rat astrocyte cultures.
Spinal Cord Atrophy and Early Motor Recovery following Transverse Myelitis in Pediatric Patients.
Pages
« first
‹ previous
…
150
151
152
153
154
155
156
157
158
…
next ›
last »